Tittes Julia, Brell Jennifer, Fritz Pia, Jonak Constanze, Stary Georg, Ressler Julia M, Künig Sarojinidevi, Weninger Wolfgang, Stöckl Johannes
Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Institute of Immunology, Medical University of Vienna, Lazarettgasse 19, 1090, Vienna, Austria.
Dermatol Ther (Heidelb). 2024 Mar;14(3):613-626. doi: 10.1007/s13555-024-01112-4. Epub 2024 Mar 8.
Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. The effects of these treatments on immune cell populations in the skin are largely unknown.
In this study, we compared the composition of cutaneous, lesional and non-lesional immune cells and blood immune cells in ixekizumab- or adalimumab-treated patients with psoriasis.
Our data reveal that both treatments efficiently downregulate T cells, macrophages and different subsets of dendritic cells (DCs) in lesional skin towards levels of healthy skin. In contrast to lesional skin, non-lesional areas in patients harbor only few or no detectable DCs compared to the skin of healthy subjects. Treatment with neither ixekizumab nor adalimumab reversed this DC imbalance in non-lesional skin of psoriatic patients.
Our study shows that anti-IL-17A and anti-TNFα therapy rebalances the immune cell repertoire of lesional skin in psoriatic patients but fails to restore the disturbed immune cell repertoire in non-lesional skin.
分别用单克隆抗体（mAb）司库奇尤单抗或阿达木单抗靶向促炎细胞因子白细胞介素17A（IL-17A）或肿瘤坏死因子α（TNFα），是治疗慢性斑块状银屑病的一种成功疗法。这些治疗方法对皮肤中免疫细胞群体的影响在很大程度上尚不清楚。
在本研究中，我们比较了接受司库奇尤单抗或阿达木单抗治疗的银屑病患者的皮肤、皮损和非皮损免疫细胞以及血液免疫细胞的组成。
我们的数据显示，两种治疗方法均能有效下调皮损皮肤中的T细胞、巨噬细胞和不同亚群的树突状细胞（DC），使其达到健康皮肤的水平。与皮损皮肤不同，与健康受试者的皮肤相比，银屑病患者非皮损区域中仅含有很少或无法检测到的DC。司库奇尤单抗和阿达木单抗治疗均未逆转银屑病患者非皮损皮肤中的这种DC失衡。
我们的研究表明，抗IL-17A和抗TNFα疗法可使银屑病患者皮损皮肤的免疫细胞组成重新平衡，但无法恢复非皮损皮肤中紊乱的免疫细胞组成。
